We are going to be talking about the kidney endpoints of the FLOW trial in some detail and the cardiovascular endpoints as well. The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist Once-Weekly Semaglutide and the FLOW Trial Results will take place on Monday, June 24, from 1:30 p.m
Research-grade FOXO4 DRI peptide targeting p53 protein interactions to selectively induce apoptosis in senescent cells for vitro studies
A better understanding of the pathways active in GLP1R -high samples could provide insight into the functional significance of GLP1R expression in prostate tissue and its role in prostatic disease
Prevents Common Dehydration Symptoms Many people on GLP-1 medications experience mild dehydration, which can cause: Headaches Muscle cramps and body aches Nausea Constipation or hard stools Fatigue and lightheadedness Trouble sleeping Since GLP-1s can slow digestion, staying hydrated helps keep your digestive system moving smoothly, preventing uncomfortable symptoms like constipation and stomach discomfort
Vercellini P, Somigliana E, Vigan P, Abbiati A, Barbara G, Fedele L
